Genmab A/S

Genmab A/S is a leading biotechnology company that specializes in developing innovative antibody therapeutics for cancer treatment. Established in 1999, the company has a strong focus on research and development, with a diverse pipeline of products targeting various cancers. Its flagship product, Darzalex, is a monoclonal antibody approved for treating multiple myeloma. Genmab is also developing potential treatments for solid tumors and hematological malignancies. The company is dedicated to improving the lives of cancer patients through novel and effective therapies and is a recognized leader in the field of antibody therapeutics.